PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,156,756 | -95.8% | 29,960 | -94.2% | 0.01% | -95.9% |
| Q3 2022 | $27,696,000 | -9.6% | 520,697 | -0.9% | 0.22% | -8.7% |
| Q2 2022 | $30,639,000 | -4.1% | 525,536 | +25.6% | 0.24% | +17.6% |
| Q1 2022 | $31,940,000 | -51.5% | 418,502 | -61.7% | 0.20% | -47.6% |
| Q4 2021 | $65,795,000 | +4.3% | 1,093,482 | -2.9% | 0.39% | +2.9% |
| Q3 2021 | $63,074,000 | +0.9% | 1,126,319 | +9.3% | 0.38% | +1.3% |
| Q2 2021 | $62,540,000 | +69.3% | 1,030,645 | +95.5% | 0.38% | +63.0% |
| Q1 2021 | $36,944,000 | -33.4% | 527,097 | -43.1% | 0.23% | -30.1% |
| Q4 2020 | $55,471,000 | +1.1% | 926,988 | +1.6% | 0.33% | -7.3% |
| Q3 2020 | $54,876,000 | -23.2% | 912,775 | -32.9% | 0.36% | -27.7% |
| Q2 2020 | $71,424,000 | +113.0% | 1,361,242 | +36.1% | 0.49% | +66.4% |
| Q1 2020 | $33,536,000 | -0.1% | 1,000,170 | +34.9% | 0.30% | +23.4% |
| Q4 2019 | $33,585,000 | +71.3% | 741,389 | +44.0% | 0.24% | +52.2% |
| Q3 2019 | $19,603,000 | -24.6% | 514,929 | -38.3% | 0.16% | -21.5% |
| Q1 2018 | $25,988,000 | -54.3% | 834,282 | -33.0% | 0.20% | -53.9% |
| Q4 2017 | $56,876,000 | +17.8% | 1,245,923 | -3.1% | 0.43% | +17.0% |
| Q3 2017 | $48,284,000 | -17.1% | 1,285,850 | +5.3% | 0.37% | -25.4% |
| Q2 2017 | $58,258,000 | -20.6% | 1,221,340 | -24.1% | 0.50% | -21.1% |
| Q1 2017 | $73,363,000 | +41.6% | 1,608,847 | +0.3% | 0.63% | +38.8% |
| Q4 2016 | $51,799,000 | +22.2% | 1,603,681 | +29.5% | 0.45% | +32.7% |
| Q3 2016 | $42,378,000 | -5.8% | 1,238,408 | -7.2% | 0.34% | -7.8% |
| Q2 2016 | $44,991,000 | +22.5% | 1,333,868 | +92.5% | 0.37% | +33.0% |
| Q1 2016 | $36,718,000 | -28.6% | 693,054 | +3.5% | 0.28% | -19.4% |
| Q4 2015 | $51,416,000 | -9.9% | 669,560 | -51.8% | 0.35% | -14.4% |
| Q3 2015 | $57,095,000 | -46.0% | 1,389,164 | -7.0% | 0.40% | -37.3% |
| Q2 2015 | $105,659,000 | +63.4% | 1,494,052 | +105.2% | 0.64% | +72.7% |
| Q1 2015 | $64,682,000 | – | 727,990 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |